Metabolic Syndrome Among People Living With HIV on Dolutegravir and Efavirenz-Based Antiretroviral Therapy in Ethiopia: A Comparative Cross-Sectional Study.

IF 2.2 Q3 INFECTIOUS DISEASES

Journal of the International Association of Providers of AIDS Care Pub Date : 2024-01-01 DOI:10.1177/23259582241303305

Mohammed Jemal, Baye Ashenef, Deresse Sinamaw, Adane Adugna, Mamaru Getinet, Temesgen Baylie, Nuredin Chura Waritu

{"title":"Metabolic Syndrome Among People Living With HIV on Dolutegravir and Efavirenz-Based Antiretroviral Therapy in Ethiopia: A Comparative Cross-Sectional Study.","authors":"Mohammed Jemal, Baye Ashenef, Deresse Sinamaw, Adane Adugna, Mamaru Getinet, Temesgen Baylie, Nuredin Chura Waritu","doi":"10.1177/23259582241303305","DOIUrl":null,"url":null,"abstract":"Purpose: This study aimed to assess the burden of metabolic syndrome among people living with HIV (PLWH) on dolutegravir (DTG)- and efavirenz (EFV)-based regimens.Methods: A hospital-based comparative cross-sectional study design was implemented from May 5, 2022, to August 5, 2022.Results: The overall prevalence of metabolic syndrome was 18.6% (32/172) for all regimens, with 25.6% (22/86) for the DTG- and 11.6% (10/86) for the EFV-based regimens (P = .019). Body mass index ≥ 25 kg/m2 (adjusted odds ratio [AOR] = 3.04; 95% confidence interval [CI]: 1.13-8.14), CD4 count ≥ 500 cells/mm3 (AOR = 3.01; 95% CI: 1.09-8.28), insufficient physical activity (AOR = 2.60; 95% CI: 1.00-6.72), and DTG-based regimen (AOR = .86; 95% CI: 1.14-7.20) were associated with metabolic syndrome.Conclusion: The prevalence of metabolic syndrome was significantly higher among PLWH on DTG-based regimens. This signifies that DTG-treated patients should be advised on lifestyle adjustments to prevent the development of metabolic syndrome.","PeriodicalId":17328,"journal":{"name":"Journal of the International Association of Providers of AIDS Care","volume":"23 ","pages":"23259582241303305"},"PeriodicalIF":2.2000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11635881/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the International Association of Providers of AIDS Care","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/23259582241303305","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: This study aimed to assess the burden of metabolic syndrome among people living with HIV (PLWH) on dolutegravir (DTG)- and efavirenz (EFV)-based regimens.

Methods: A hospital-based comparative cross-sectional study design was implemented from May 5, 2022, to August 5, 2022.

Results: The overall prevalence of metabolic syndrome was 18.6% (32/172) for all regimens, with 25.6% (22/86) for the DTG- and 11.6% (10/86) for the EFV-based regimens (P = .019). Body mass index ≥ 25 kg/m² (adjusted odds ratio [AOR] = 3.04; 95% confidence interval [CI]: 1.13-8.14), CD4 count ≥ 500 cells/mm³ (AOR = 3.01; 95% CI: 1.09-8.28), insufficient physical activity (AOR = 2.60; 95% CI: 1.00-6.72), and DTG-based regimen (AOR = .86; 95% CI: 1.14-7.20) were associated with metabolic syndrome.

Conclusion: The prevalence of metabolic syndrome was significantly higher among PLWH on DTG-based regimens. This signifies that DTG-treated patients should be advised on lifestyle adjustments to prevent the development of metabolic syndrome.

查看原文本刊更多论文

在埃塞俄比亚，以多替格拉韦和依非韦伦为基础的抗逆转录病毒治疗的艾滋病毒感染者代谢综合征：一项比较横断面研究。

目的：本研究旨在评估以多替格拉韦（DTG）和依非韦伦（EFV）为基础的方案对HIV感染者（PLWH）代谢综合征的负担。方法：于2022年5月5日至2022年8月5日实施以医院为基础的比较横断面研究设计。结果：所有方案中代谢综合征的总体患病率为18.6%(32/172)，其中以DTG为基础的方案为25.6%(22/86)，以efv为基础的方案为11.6% (10/86)（P = 0.019）。体重指数≥25 kg/m2(校正优势比[AOR] = 3.04；95%置信区间[CI]: 1.13-8.14)， CD4计数≥500个细胞/mm3 (AOR = 3.01；95% CI: 1.09-8.28)，身体活动不足(AOR = 2.60；95% CI: 1.00-6.72)，以及基于dtg的方案(AOR = .86；95% CI: 1.14-7.20)与代谢综合征相关。结论：以dtg为基础的PLWH组代谢综合征患病率明显增高。这表明，dtg治疗的患者应建议调整生活方式，以防止代谢综合征的发展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊